The primary goal is to develop a multidomain intervention program focused on preserving global or regional brain volume and functions while simultaneously improving physical mobility and cognitive functions in older individuals with mobility frailty. This initiative seeks to unravel the brain-muscle axis mechanisms contributing to the accelerated functional declines observed in older populations. Moreover, our objective includes examining the relationships between the intervention and a broad spectrum of clinical characteristics, phenotypic traits, biochemical profiles, myokines, proteomics, metabolomics, brain imaging, and our previously identified discoveries involving exosomal miRNA.
This study is a randomized controlled trial of 12-month multidomain intervention program among community-living older adults with early physical or cognitive impairments. Inclusion criteria are: (1) community-dwelling adults aged ≥ 65 years, (2) slow gait speed (\<1 m/s in 6-meter walk test) or weakness (dominant handgrip strength \<28 kg in men, \<18 kg in women); subjects with the following conditions will be excluded: (1) established diagnosis of dementia, Parkinsonism or other neurodegenerative disease (2) disable status: mobility-limiting conditions, (3) active, acute diseases receiving treatment, such as cancer, heart failure, COPD and so on, (4) estimated life expectancy \<12 months, (5) current nursing home residents.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
102
Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University
Taipei, Taiwan
Change in brain structures on MRI
Change in brain structures from baseline to 12 months in all participants
Time frame: baseline, 12 month
Change in Physical performance
Change in hand-grip strength (kg), six-meter walking speed (m/s), and 5 times sit to stand test from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Life quality SF12
measured by the 12-Item Short Form Health Survey (SF-12).
Time frame: baseline, 6, 12 month
Change in Complete blood count
Change in Complete blood count from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in Nutrition intake
measured by Mini-nutritional assessment questionnaire. ranged 0-30, higher values represent a better condition
Time frame: baseline, 6, 12 month
Change in depression
measured by the Center for Epidemiological Studies-Depression (CES-D) ranged 0-60, higher values represent a worse condition
Time frame: baseline, 6, 12 month
Change in cognitive ability
Change in cognitive function measure by MoCA ranged 0-30, higher values represent a better condition
Time frame: baseline, 6, 12 month
Change in International Physical Activity Questionnaire (IPAQ)
Change in physical activity measured by IPAQ, indicates that spent being physically active than the prior 7 days.There are no established thresholds for presenting MET-minutes, the IPAQ Research Committee proposes that reported as comparisons of median values and interquartile ranges for different populations from baseline to 12 months in all participants. The higher values represent a better activity.
Time frame: baseline, 6, 12 month
Change in Vitamin D3 25-OH
Change in Vitamin D3 25-OH concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in DHEA-S
Change in DHEA-S concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in IGF-1
Change in IGF-1 concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in Homocysteine
Change in Homocysteine concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in hs-CRP
Change in hs-CRP concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in Zinc
Change in Zinc concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in TSH
Change in TSH concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in Myostatin
Change in Myostatin concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in Activing A
Change in Activing A concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in Follistatin
Change in Follistatin concentration from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in Relative appendicular skeletal muscle index (RASM)
Change in RASM from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
Change in body fat %
Change in body fat % from baseline to 12 months in all participants
Time frame: baseline, 6, 12 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.